Medios AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MEDOF research report →
About the company
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through three segments: Patient-Specific Therapies; International Business; and Pharmaceutical Supply. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies.
- CEO
- Michael Mulberry
- IPO
- 2021
- Employees
- 472
- HQ
- Berlin, BC, DE
Price Chart
- Market Cap
- $1.28B
- P/E
- 22.58
- P/S
- 0.15
- P/B
- 0.59
- EV/EBITDA
- 5.22
- Div Yield
- 0.00%
- Gross Margin
- 6.92%
- Op Margin
- 2.06%
- Net Margin
- 0.66%
- ROE
- 2.69%
- ROIC
- 2.99%
- Revenue
- $2.08B · 10.39%
- Net Income
- $15.37M · 22.45%
- EPS
- $0.61 · 19.61%
- Op Income
- $42.41M
- FCF YoY
- -34.70%
- 52W High
- $50.00
- 52W Low
- $13.64
- 50D MA
- $50.00
- 200D MA
- $50.00
- Beta
- 1.32
- Avg Volume
- 1.30K
Get TickerSpark's AI analysis on MEDOF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our MEDOF coverage
Recent articles, reports, and earnings notes.
No research on MEDOF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MEDOF report →Similar companies
Peers in the same neighborhood.